Artiva Biotherapeutics宣布AlloNK（其异基因、非基因修饰的自然杀伤细胞治疗候选药物）的临床、安全性和翻译数据

2026-06-08 18:34

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis
Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases
Rheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trial
Safety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapy
U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for the treatment of refractory rheumatoid arthritis
Artiva to host virtual webcast today at 8:15 am EDT, featuring Dr. Paul Emery, Arthritis UK professor of rheumatology at the University of Leeds